Although the efficacy of ICI in NSCLC patients harboring oncogenic alterations is poor, the PD-L1 status is still believed to be the most effective predictive biomarker for identifying patients most likely to benefit from ICI.[8,23] Except high PD-L1 levels, Limited data indicated that smoking history,[24] L858R mutation subtype,[25] or uncommon EGFR mutation type[26,27] are also associated with better outcomes following treatment with immunotherapy. Here, EGFR is linked to non-small cell lung carcinoma.